Clearmind Medicine Inc. (Vancouver, Canada), a clinical-stage biotech focused on neuroplastogen therapeutics, announced the filing of a European patent application covering novel psychedelic compounds intended for the treatment of post-traumatic stress disorder (PTSD) and related mental health conditions. The application was filed with the European Patent Office and forms part of Clearmind’s exclusive worldwide licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. The filing is scientifically notable because the compounds are characterized as non-hallucinogenic, second-generation neuroplastogen-derived molecules, a design approach that attempts to retain the synaptic remodeling properties associated with classical psychedelics while removing the perceptual distortion that has historically complicated clinical development and regulatory review in the psychedelic PTSD treatment space.
The Clearmind Medicine patent filing adds to a portfolio the company describes as comprising 19 patent families and 31 granted patents. The European application extends that portfolio into one of the world’s largest pharmaceutical markets and is directly tied to the company’s exclusive rights, under the Yissum agreement, to develop, manufacture, and commercialize novel compounds originating from Hebrew University research. Clearmind holds responsibility for advancing the development program in accordance with applicable regulatory requirements.
The specific molecular structures, receptor binding profiles, and mechanism-of-action details for the compounds covered by this European patent application are not disclosed in the available source material. The compounds are described broadly as novel, non-hallucinogenic, and derived from neuroplastogen research. No clinical trial identifiers, Phase designations, or efficacy or safety data have been disclosed in connection with this filing. Specific clinical results for this asset remain undisclosed.
The neuroplastogen concept centers on the capacity of certain psychedelic-derived molecules to promote structural and functional plasticity in neural circuits, particularly those implicated in fear memory consolidation and extinction — processes that are dysregulated in PTSD. Classical psychedelics such as psilocybin and MDMA have demonstrated the ability to facilitate this kind of synaptic remodeling, but their hallucinogenic and entactogenic properties introduce complexity in trial design, regulatory scheduling, and patient access. Second-generation neuroplastogen compounds, as Clearmind describes its pipeline, are designed to decouple the plasticity-promoting pharmacology from the subjective perceptual effects, potentially enabling more straightforward regulatory pathways and broader patient applicability. Whether the specific compounds covered by this European patent application achieve that pharmacological separation has not been confirmed by disclosed data.
Context and competitive landscape
The psychedelic PTSD treatment field has attracted a substantial number of developers pursuing both classical and modified psychedelic-derived compounds, and Clearmind’s European patent application enters a landscape shaped by several well-resourced programs at varying stages of clinical development.
The most clinically advanced direct mechanistic peer is MDMA-assisted therapy, developed by Lykos Therapeutics (formerly MAPS Public Benefit Corporation, USA). Lykos submitted a new drug application to the US FDA for MDMA-assisted therapy in PTSD, but the agency issued a complete response letter in August 2024, requesting an additional Phase III trial before approval could be considered. MDMA functions as a serotonin, dopamine, and norepinephrine releasing agent with entactogenic properties, and its proposed therapeutic mechanism in PTSD involves reduction of fear response during trauma processing sessions conducted under therapist supervision. The program has been evaluated in multiple Phase III studies, though the US FDA’s request for additional data has extended the regulatory timeline. MDMA is a scheduled substance, and its hallucinogenic and entactogenic profile places it in a different pharmacological category from the non-hallucinogenic compounds Clearmind describes.
Psilocybin, the active component of several programs under development, represents another mechanistic reference point. Compass Pathways (UK/USA) is developing Comp360 (psilocybin) for treatment-resistant depression and has conducted Phase IIb studies, with Phase III programs underway. While Compass’s primary focus is depression rather than PTSD, the serotonin 2A receptor agonism that underlies psilocybin’s neuroplastogenic effects is relevant to the broader mechanistic category Clearmind is working within. Separately, Usona Institute (USA) is advancing psilocybin for major depressive disorder in Phase III development. Neither program has disclosed data specific to PTSD as a primary indication, but both represent the clinical frontier of serotonergic neuroplastogen therapeutics. Psilocybin’s hallucinogenic properties again contrast with the non-hallucinogenic profile Clearmind attributes to its compounds.
Among companies more directly focused on non-hallucinogenic neuroplastogen-derived compounds for psychiatric indications, Delix Therapeutics (USA) has disclosed a pipeline of tabernanthalog and related compounds designed to promote neural plasticity without producing hallucinogenic effects, targeting indications including PTSD and substance use disorder. Delix’s compounds are in preclinical and early clinical evaluation. Entheogen-derived compound development at this stage of the field remains largely preclinical or in early Phase I work, and no non-hallucinogenic neuroplastogen has yet reached late-stage clinical development or received regulatory approval specifically for PTSD.
On the functional benchmark side, the PTSD treatment market is currently served by two US FDA-approved pharmacological agents: sertraline and paroxetine, both selective serotonin reuptake inhibitors approved for PTSD. These agents address symptom burden through chronic monoamine modulation rather than through acute neuroplasticity induction. Prazosin, an alpha-1 adrenergic antagonist, is used off-label for PTSD-related nightmares. None of these approved agents share a mechanism with neuroplastogen-derived compounds, and their clinical profiles are defined by modest average effect sizes and significant non-response rates in the PTSD population, which provides the rationale for the mechanistic approaches being pursued by Clearmind and its peers in the biotech PTSD clinical trial space.
This article was generated with AI assistance and reviewed and edited by the AllSci editorial team
Explore more at AllSci News: https://allsci.com/news/